secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001171843-23-003188
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q1 net loss $5.7M; agenT-797 shows durable responses in solid tumors
--------------------------------------------------------------------------------

- Net loss $5.7M ($0.17/share) vs $7.8M ($0.23) in Q1 2022; cash $14.9M at March 31, 2023.
- agenT-797 + anti-PD-1 achieved 42% tumor reduction in metastatic gastric cancer lasting >9 months; durable disease stabilization in anti-PD-1 refractory NSCLC.
- Initiating phase 1/2 expansion studies in NSCLC and gastric cancer; majority costs planned for external non-dilutive grant funding.
- Upcoming presentations: FAP-CAR-iNKT at ASGCT May 19; agenT-797 in viral ARDS at ATS May 21.
- Manufacturing capacity 5,000 doses/year, rapidly expanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323003188/0001171843-23-003188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323003188/f8k_051123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-003188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer